Tenax Therapeutics (NASDAQ: TENX) is one of 32 publicly-traded companies in the “Commercial physical research” industry, but how does it contrast to its competitors? We will compare Tenax Therapeutics to related businesses based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, institutional ownership and dividends.
Volatility & Risk
Tenax Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Tenax Therapeutics’ competitors have a beta of 3.59, meaning that their average stock price is 259% more volatile than the S&P 500.
This table compares Tenax Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tenax Therapeutics Competitors||-264.40%||-15.96%||-9.71%|
Earnings and Valuation
This table compares Tenax Therapeutics and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Tenax Therapeutics||N/A||-$6.81 million||-0.15|
|Tenax Therapeutics Competitors||$744.96 million||$42.30 million||12.53|
Tenax Therapeutics’ competitors have higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent recommendations and price targets for Tenax Therapeutics and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tenax Therapeutics Competitors||171||714||1521||70||2.60|
As a group, “Commercial physical research” companies have a potential upside of 8.93%. Given Tenax Therapeutics’ competitors higher probable upside, analysts plainly believe Tenax Therapeutics has less favorable growth aspects than its competitors.
Institutional & Insider Ownership
16.3% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 45.7% of shares of all “Commercial physical research” companies are held by institutional investors. 3.3% of Tenax Therapeutics shares are held by insiders. Comparatively, 15.6% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Tenax Therapeutics competitors beat Tenax Therapeutics on 9 of the 10 factors compared.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.